08 May 2025

Xbrane Biopharma releases Interim Report January-March 2025

05 May 2025

Announcement from the annual general meeting in Xbrane Biopharma AB

04 May 2025

Invitation to presentation of Xbrane Biopharma’s interim report January – March 2025 on May 8, 2025

14 Apr 2025

Announcement from extra general meeting in Xbrane Biopharma AB

02 Apr 2025

NOTICE OF ANNUAL GENERAL MEETING IN XBRANE BIOPHARMA AB

31 Mar 2025

XBRANE BIOPHARMA RELEASES ANNUAL AND SUSTAINABILITY REPORT FOR 2024

20 Mar 2025

Notice of Extra General Meeting in Xbrane Biopharma AB

20 Mar 2025

Xbrane has entered into an agreement to sell XB003 (Cimzia biosimilar candidate) and parts of its organization to Alvotech for a total consideration of SEK 275 million

20 Feb 2025

Xbrane Biopharma releases Year-end Report 2024

17 Feb 2025

Invitation to presentation of Xbrane Biopharma’s Year-end report 2024 on February 20, 2025

31 Jan 2025

The number of shares and votes in Xbrane has changed as a result of 2,706,898 shares being issued during January through the exercise of warrants in December 2024.

09 Jan 2025

Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.

31 Dec 2024

XBRANE RE-SUBMITS BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA

18 Dec 2024

Xbrane announces outcome of exercise of warrants of series TO1

02 Dec 2024

XBRANE BIOPHARMA’S PRINCIPAL OWNER SYSTEMATIC GROUP PROVIDES A SHORT-TERM LOAN OF SEK 20 M TO THE COMPANY